Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Tremelimumab (Primary)
- Indications Bladder cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 13 Aug 2019 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 13 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 31 Jan 2019 Status changed from not yet recruiting to recruiting.